文献速递眼底病与葡萄膜炎

美国联邦医疗保险B部分按服务收费受益人中糖尿病黄斑水肿与视力威胁性糖尿病视网膜病变的患病率及治疗趋势

Trends in Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy Among Medicare Part B Fee-for-Service Beneficiaries.
PubMed 文献 · JAMA Ophthalmol · 2022-01-01

这项横断面研究利用2009至2018年美国联邦医疗保险B部分按服务收费受益人的理赔数据,分析65岁及以上糖尿病患者中糖尿病黄斑水肿(DME)或视力威胁性糖尿病视网膜病变(VTDR)的年患病率及治疗趋势。结果显示,任何DME和DME/VTDR的患病率均上升,抗血管内皮生长因子(VEGF)治疗比例增加,而激光光凝和玻璃体切除术比例下降。

要点

  • 2009至2018年,糖尿病患者中任何DME年患病率从1.0%升至3.3%,DME/VTDR从2.8%升至4.3%。
  • 任何DME患者抗VEGF治疗比例从15.7%升至35.2%,VTDR伴DME患者从20.2%升至47.6%。
  • 任何DME患者激光光凝比例从45.5%降至12.5%,VTDR不伴DME患者从22.5%降至5.8%。

核心结论

  • 2009至2018年间,联邦医疗保险B部分按服务收费受益人中DME或VTDR患病率上升,同时抗VEGF治疗增加,激光光凝和玻璃体切除术减少。

研究设计与样本

  • 横断面研究,使用美国联邦医疗保险与医疗补助服务中心可识别研究文件,分析2009至2018年65岁及以上连续参加B部分按服务收费保险且符合糖尿病诊断标准的受益人理赔数据。

主要发现

  • 2018年有6 960 823名受益人(27.4%)患有糖尿病,其中49.7%年龄65至74岁,52.7%为女性,75.7%为非西班牙裔白人。
  • 2009至2018年,糖尿病患者中任何DME的年患病率从1.0%升至3.3%,DME/VTDR从2.8%升至4.3%。
  • 任何DME患者抗VEGF年患病率从15.7%升至35.2%,VTDR伴DME患者从20.2%升至47.6%。
  • 任何DME患者激光光凝年患病率从45.5%降至12.5%,VTDR伴DME患者从54.0%降至20.3%,VTDR不伴DME患者从22.5%降至5.8%。
  • 所有3组中,2018年玻璃体切除术患病率均不足2009年的一半;2018年任何DME和DME/VTDR患病率在西班牙裔(分别为5.0%和7.0%)和黑人(分别为4.5%和6.2%)中最高,非西班牙裔白人最低(分别为3.0%和3.8%);DME/VTDR患者中抗VEGF在非西班牙裔白人中患病率最高(30.3%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: While diabetes prevalence among US adults has increased in recent decades, few studies document trends in diabetes-related eye disease. OBJECTIVE: To examine 10-year trends (2009-2018) in annual prevalence of Medicare beneficiaries with diabetes with a diagnosis of diabetic macular edema (DME) or vision-threatening diabetic retinopathy (VTDR) and trends in treatment. DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional study using Centers for Medicare & Medicaid Services research identifiable files, data for patients 65 years and older were analyzed from claims. Beneficiaries were continuously enrolled in Medicare Part B fee-for-service (FFS) insurance for the calendar year and had a diagnosis of diabetes on 1 or more inpatient claims or 2 or more outpatient claims during the calendar year or a 1-year look-back period. MAIN OUTCOMES AND MEASURES: Using diagnosis and procedure codes, annual prevalence was determined for beneficiaries with 1 or more claims for (1) any DME, (2) either DME or VTDR, and (3) anti-vascular endothelial growth factor (VEGF) injections, laser photocoagulation, or vitrectomy, stratified by any DME, VTDR with DME, and VTDR without DME. Racial and ethnic disparities in diagnosis and treatment are presented for 2018. RESULTS: In 2018, 6 960 823 beneficiaries (27.4%) had diabetes; half were aged 65 to 74 years (49.7%), half (52.7%) were women, and 75.7% were non-Hispanic White. From 2009 to 2018, there was an increase in the annual prevalence of beneficiaries with diabetes who had 1 or more claims for any DME (1.0% to 3.3%) and DME/VTDR (2.8% to 4.3%). Annual prevalence of anti-VEGF increased, particularly among patients with any DME (15.7% to 35.2%) or VTDR with DME (20.2% to 47.6%). Annual prevalence of laser photocoagulation decreased among those with any DME (45.5% to 12.5%), VTDR with DME (54.0% to 20.3%), and VTDR without DME (22.5% to 5.8%). Among all 3 groups, prevalence of vitrectomy in 2018 was less than half that in 2009. Prevalence of any DME and DME/VTDR was highest among Hispanic beneficiaries (5.0% and 7.0%, respectively) and Black beneficiaries (4.5% and 6.2%, respectively) and lowest among non-Hispanic White beneficiaries (3.0% and 3.8%, respectively). Among those with DME/VTDR, anti-VEGF was most prevalent among non-Hispanic White beneficiaries (30.3%). CONCLUSIONS AND RELEVANCE: From 2009 to 2018, prevalence of DME or VTDR increased among Medicare Part B FFS beneficiaries alongside an increase in anti-VEGF treatment and a decline in laser photocoagulation and vitrectomy.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Lundeen EA, Andes LJ, Rein DB, et al. Trends in Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy Among Medicare Part B Fee-for-Service Beneficiaries. JAMA Ophthalmol. 2022. PMID: 35238912. doi:10.1001/jamaophthalmol.2022.0052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。